Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patientsYu Sawada, Tetsuya Nakatsura, Daisuke Nobuoka et al.|OncoImmunology|2016Cited by 178
Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinomaKazuya Ofuji, Tetsuya Nakatsura, Keigo Saito et al.|Oncotarget|2016Cited by 28
Abstract CT115: Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patientsYu Sawada, Tetsuya Nakatsura, Toshiaki Yoshikawa et al.|Cancer Research|2015Cited by 0